Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Meloxicam

S Noble1, J A Balfour

  • 1Adis International Limited, Auckland, New Zealand.

Drugs
|March 1, 1996
PubMed
Summary
This summary is machine-generated.

Meloxicam, a novel nonsteroidal anti-inflammatory drug (NSAID), demonstrates superior gastrointestinal safety and comparable efficacy for treating rheumatoid arthritis and osteoarthritis compared to other NSAIDs.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Methods for think-aloud interviews in health-related resource-use research: the PECUNIA RUM instrument.

Expert review of pharmacoeconomics & outcomes research·2023
Same author

The Rise of Supportive Oncology: A Revolution in Cancer Care.

Clinical oncology (Royal College of Radiologists (Great Britain))·2023
Same author

Proper understanding of recurrent stress urinary incontinence treatment in women (PURSUIT): a randomised controlled trial of endoscopic and surgical treatment.

Trials·2022
Same author

COVID-19 confessions: a qualitative exploration of healthcare workers experiences of working with COVID-19.

BMJ open·2020
Same author

Modelling the lifetime cost-effectiveness of radical prostatectomy, radiotherapy and active monitoring for men with clinically localised prostate cancer from median 10-year outcomes in the ProtecT randomised trial.

BMC cancer·2020
Same author

Measuring functional limitations after venous thromboembolism: Optimization of the Post-VTE Functional Status (PVFS) Scale.

Thrombosis research·2020
Same journal

Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

Drugs·2026
Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026
Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026
Same journal

Relacorilant: First Approval.

Drugs·2026
Same journal

Developmental Progress and Future Potential for Inhaled Biologics in the Treatment of Respiratory Diseases.

Drugs·2026
Same journal

Linerixibat: First Approval.

Drugs·2026
See all related articles

Area of Science:

  • Pharmacology
  • Rheumatology
  • Gastroenterology

Background:

  • Nonsteroidal anti-inflammatory drugs (NSAIDs) are widely used for inflammatory conditions.
  • Traditional NSAIDs inhibit both cyclo-oxygenase-1 (COX-1) and cyclo-oxygenase-2 (COX-2) enzymes.
  • COX-1 inhibition is linked to gastrointestinal and renal adverse effects.

Purpose of the Study:

  • To evaluate the efficacy and gastrointestinal safety of meloxicam.
  • To compare meloxicam with other NSAIDs in treating rheumatoid arthritis and osteoarthritis.

Main Methods:

  • In vitro and in vivo studies assessing COX-1 and COX-2 inhibition.
  • Animal models evaluating anti-inflammatory effects and ulcerogenic potential.
  • Endoscopic evaluation of gastrointestinal mucosal damage in healthy volunteers.

Related Experiment Videos

  • Comparative clinical trials in patients with rheumatoid arthritis and osteoarthritis.

    • Main Results:

    • Meloxicam exhibits greater selective inhibition of COX-2 compared to COX-1.
    • Animal studies showed a better therapeutic ratio for meloxicam.
    • Healthy volunteers experienced less gastrointestinal damage with meloxicam than with piroxicam.
    • Clinical trials indicated meloxicam's efficacy was comparable to piroxicam, naproxen, and diclofenac.
    • Meloxicam demonstrated improved gastrointestinal tolerability over comparator NSAIDs.

    Conclusions:

    • Meloxicam offers a favorable therapeutic profile for managing inflammatory conditions.
    • Its selective COX-2 inhibition contributes to enhanced gastrointestinal safety.
    • Meloxicam is a viable and well-tolerated treatment option for rheumatoid arthritis and osteoarthritis.